2022年度業績

【英文論文】

Akaike K, Saruwatari K, Matsushima R, Fujino K, Morinaga J, Oda S, Takahashi H, Shiraishi S, Okabayashi H, Hamada S, Tomita Y, Masunaga A, Saeki S, Ikeda K, Ichiyasu H, Suzuki M, Sakagami T. Clinical impact of SUVmax of interstitial lesions in lung cancer patients with interstitial lung disease who underwent pulmonary resection. J Thorac Dis. in press.

Sato Y, Sumikawa H, Shibaki R, Morimoto T, Sakata Y, Oya Y, Tamiya M, Suzuki H, Matsumoto H, Yokoi T, Hashimoto K, Kobe H, Hino A, Inaba M, Tsukita Y, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Sakata S, Fujimoto D. Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting.
Chest. 2022. In press. doi: 10.1016/j.chest.2022.05.035.

Ikeda T and Tomita Y. Statistical concern regarding the relationship of change in mucus plug score with airflow over time.
American Journal of Respiratory and Critical Care Medicine . 2022 Jul 23.
doi: 10.1164/rccm.202207-1273LE.

Tomita Y, Goto Y, Sakata S, Imamura K, Minemura A, Oka K, Hayashi A, Jodai T, Akaike K, Anai M, Hamada S, Iyama S, Saruwatari K, Saeki S, Takahashi M, Ikeda T, Sakagami T. Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors. OncoImmunology. 2022 May 27;11(1):2081010.

Hirotake Tsukamoto, Yoshihiro Komohara, Yusuke Tomita, Yuji Miura,Takanobu Motoshima, Kosuke Imamura, Toshiki Kimura, Tokunori Ikeda, Yukio Fujiwara, Hiromu Yano, Tomomi Kamba, Takuro Sakagami, Hiroyuki Oshiumi. Aging-associated and CD4 T cell-dependent ectopic CXCL13 activation predisposes to anti-PD-1 therapy-induced adverse events. Proc Natl Acad Sci U S A. 2022. 119 (29) e2205378119.

Cao S, Zhang Y, Zhou Y, Rong W, Wang Y, Ling X, Zhang L, Li J, Tomita Y, Watanabe S, Nakada T, Seki N, Hida T, Dermime S, Zhong R, Zhong H. A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer.
Transl Lung Cancer Res. 2022 Apr;11(4):607-616.

Matsubara E, Komohara Y, Esumi S, Shinchi Y, Ishizuka S, Mito R, Pan C, Yano H, Kobayashi D, Fujiwara Y, Ikeda K, Sakagami T, Suzuki M. SPP1 Derived from Macrophages Is Associated with a Worse Clinical Course and Chemo-Resistance in Lung Adenocarcinoma.
Cancers. 2022; 14(18):4374.

Ami Aoki, Akira Saito, Kenjiro Shima, Yosuke Kimura, Katsuaki Asakawa, Riuko Ohashi, Hajime Umezu, Takuro Sakagami, Hiroshi Moriyama, Toshiaki Kikuchi, A Case Report of Occupational Lung Disease Caused by Exposure to Polytetrafluoroethylene.
Internal Medicine 2022 May 21. doi: 10.2169/internalmedicine.9008-21.

Shinchi, Y., Ishizuka, S., Komohara, Y. et al. The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma.
Cancer Immunol Immunother 71, 2645–2661 (2022).

Sakata S, Otsubo K, Yoshida H, Ito K, Nakamura A, Teraoka S, Matsumoto N, Shiraishi Y, Haratani K, Tamiya M, Ikeda S, Miura S, Tanizaki J, Omori S, Yoshioka H, Hata A, Yamamoto N, Nakagawa K. Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.
Cancer Sci. 2022;113:221-228.


Hirose M, Ishimaru Y, Sakata S, Sakagami T. Rapid Shrinkage of Retroperitoneal Lymphangioleiomyoma after Sirolimus Initiation.
Intern Med. 2022;61:2081-2082.

Fujimoto D, Akamatsu H, Morimoto T, Wakuda K, Sato Y, Kawa Y, Yokoyama T, Tamiya M, Hiraoka R, Shingu N, Ikeda H, Tamiya A, Kanazu M, Miyauchi E, Miura S, Yanai M, Yomota M, Morinaga R, Yokoi T, Hata A, Suzuki H, Matsumoto H, Sakata S, Furuya N, Harutani Y, Nakachi I, Otsuki A, Uematsu S, Hara S, Yokoo K, Sugimoto T, Yamamoto N. Histologic transformation of epidermal growth factor receptor-mutated lung cancer.
Eur J Cancer. 2022;166:41-50.


Hayashi H, Yonesaka K, Nakamura A, Fujimoto D, Azuma K, Sakata S, Tachihara M, Ikeda S, Yokoyama T, Hataji O, Yano Y, Hirano K, Daga H, Okada H, Chiba Y, Sakai K, Nishio K, Yamamoto N, Nakagawa K. Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).
Lung Cancer. 2022;168:38-45.


Anai M, Saruwatari K, Ikeda T, Oda S, Tajima Y, Jodai T, Sakata S, Iyama S, Tomita Y, Saeki S, Ichiyasu H, Sakagami T. Clinical impact of cerebral infarction in patients with non-small cell lung cancer.
Int J Clin Oncol. 2022 May;27(5):863-870.

Moriyasu Anai, Chieko Yoshida, Kazutaka Ozono, Hirotsugu Furukawa, Yuko Ishimaru, Shinya Sakata, Koichi Saruwatari, Kei Muramoto, Yusuke Tomita, Sho Saeki, Hidenori Ichiyasu, and Takuro Sakagami. Successful concomitant therapy with mepolizumab and dupilumab for atypical eosinophilic granulomatosis with polyangiitis.
Allergol Int. 2022 Apr;71(2):259-261.

Tamanoi D, Saruwatari K, Imamura K, Sato R, Jodai T, Hamada S, Tomita Y, Saeki S, Ueno S, Yonemura Y, Ichiyasu H, Sakagami T.
Pembrolizumab-related Immune Thrombocytopenia in a Patient with Lung Adenocarcinoma Treated by Radiotherapy: Potential Immune-related Adverse Event Elicited by Radiation Therapy.
Intern Med. 2022;61(11):1731-1734.

Copyright© 2022 熊本大学大学院生命科学研究部 呼吸器内科学分野 All rights reserved.